{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-000924","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.310522+00:00","generated_at":"2026-06-20T17:45:10.783675+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nuwellis reports preliminary Q4 revenue of $2.3M, up 42% YoY; FY22 revenue $8.5M, up 8%","bullets":["Preliminary Q4 2022 revenue $2.3M, up 42% YoY; full-year 2022 revenue $8.5M, up 8% YoY.","Pediatrics segment grew 92% YoY; Heart Failure +47%; Critical Care +24%.","Growth driven by commercial team expansion and market penetration beyond heart failure.","CEO cites strong sales momentum and commitment to making Aquadex SmartFlow standard of care."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-000924","json":"https://secwatch.observer/filing/0001140361-23-000924.json","markdown":"https://secwatch.observer/filing/0001140361-23-000924.md","text":"https://secwatch.observer/filing/0001140361-23-000924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123000924/0001140361-23-000924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123000924/brhc10046422_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:45:10.783675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1eb4a4a99badfe313d0eaa0af0ba1334039018cb","claim":"Nuwellis, Inc. reported the fourth quarter and full year 2022 results: revenue approximately $2.3 million and $8.5 million.","evidence_excerpt":"preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be approximately $2.3 million and $8.5 million, respectively, representing an increase of 42% and 8% over the same periods last year. The fourth quarter growth rate reflects benefits from the Company’s","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123000924/0001140361-23-000924-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2022"},{"label":"Revenue","value":"approximately $2.3 million and $8.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}